HK1203149A1 - Novel dosage form and formulation of abediterol - Google Patents

Novel dosage form and formulation of abediterol

Info

Publication number: HK1203149A1
Authority: HK; Hong Kong
Prior art keywords: abediterol; formulation; dosage form; novel dosage; novel
Prior art date: 2012-05-31

Application number

HK15103713.3A

Other languages

English (en)

Chinese (zh)

Inventor

Ruiz Sandrine Allain

Nunez Beatriz Seoane

Miquel Serra Gonzalo De

Original Assignee

Almirall Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-05-31

Filing date

2015-04-16

Publication date

2015-10-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46317311&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1203149(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-04-16 Application filed by Almirall Sa filed Critical Almirall Sa

2015-10-23 Publication of HK1203149A1 publication Critical patent/HK1203149A1/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Otolaryngology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)

HK15103713.3A 2012-05-31 2015-04-16 Novel dosage form and formulation of abediterol HK1203149A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP12382221.5A EP2668941A1 (en)	2012-05-31	2012-05-31	Novel dosage form and formulation of abediterol
US201261660003P	2012-06-15	2012-06-15
PCT/EP2013/061181 WO2013178742A1 (en)	2012-05-31	2013-05-30	Novel dosage form and formulation of abediterol

Publications (1)

Publication Number	Publication Date
HK1203149A1 true HK1203149A1 (en)	2015-10-23

Family

ID=46317311

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK15103713.3A HK1203149A1 (en)	2012-05-31	2015-04-16	Novel dosage form and formulation of abediterol

Country Status (29)

Country	Link
US (2)	US20150140099A1 (xx)
EP (2)	EP2668941A1 (xx)
JP (1)	JP6272836B2 (xx)
KR (2)	KR20180104197A (xx)
CN (1)	CN104394852A (xx)
AR (1)	AR091233A1 (xx)
AU (1)	AU2013269565B2 (xx)
BR (1)	BR112014029735A2 (xx)
CA (1)	CA2871358C (xx)
CL (1)	CL2014003286A1 (xx)
CO (1)	CO7141434A2 (xx)
CR (1)	CR20140540A (xx)
DO (1)	DOP2014000271A (xx)
EA (1)	EA201401354A1 (xx)
EC (1)	ECSP14028814A (xx)
HK (1)	HK1203149A1 (xx)
IL (1)	IL235831B (xx)
IN (1)	IN2014DN08672A (xx)
MX (1)	MX2014014350A (xx)
MY (1)	MY184654A (xx)
NI (1)	NI201400139A (xx)
NZ (1)	NZ701261A (xx)
PE (1)	PE20150171A1 (xx)
PH (1)	PH12014502662A1 (xx)
SG (3)	SG10201913424SA (xx)
TW (1)	TWI610690B (xx)
UY (1)	UY34838A (xx)
WO (1)	WO2013178742A1 (xx)
ZA (1)	ZA201407405B (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2641900A1 (en)	2012-03-20	2013-09-25	Almirall, S.A.	Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
US20150224197A1 (en) *	2012-07-05	2015-08-13	Arven Ilac Sanayi Ve Ticaret A.S.	Inhalation compositions
MA40027A (fr) *	2014-06-18	2015-12-23	Cipla Ltd	Composition pharmaceutique comprenant un bêta-2 agoniste et un agent anticholinergique
WO2019142214A1 (en) *	2018-01-19	2019-07-25	Cipla Limited	Pharmaceutical composition comprising tiotropium for inhalation
US11938277B2 (en)	2018-05-22	2024-03-26	C. R. Bard, Inc.	Catheterization system and methods for use thereof
WO2020033752A1 (en)	2018-08-10	2020-02-13	C. R. Bard, Inc.	Automated urine-output-measurement systems and methods thereof
US12083261B2 (en)	2020-06-05	2024-09-10	C. R. Bard, Inc.	Automated fluid output monitoring
US12055249B2 (en)	2020-07-21	2024-08-06	C. R. Bard, Inc.	Automatic fluid flow system with retractable connection
US11931151B2 (en)	2020-12-22	2024-03-19	C. R. Bard, Inc.	Automated urinary output measuring system

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT7920688V0 (it)	1979-02-05	1979-02-05	Chiesi Paolo Parma	Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore.
DE3274065D1 (de)	1981-07-08	1986-12-11	Draco Ab	Powder inhalator
US4570630A (en)	1983-08-03	1986-02-18	Miles Laboratories, Inc.	Medicament inhalation device
FI69963C (fi)	1984-10-04	1986-09-12	Orion Yhtymae Oy	Doseringsanordning
DE3927170A1 (de)	1989-08-17	1991-02-21	Boehringer Ingelheim Kg	Inhalator
IT1237118B (it)	1989-10-27	1993-05-18	Miat Spa	Inalatore multidose per farmaci in polvere.
GB9004781D0 (en)	1990-03-02	1990-04-25	Glaxo Group Ltd	Device
GB9015522D0 (en)	1990-07-13	1990-08-29	Braithwaite Philip W	Inhaler
WO1992003175A1 (en)	1990-08-11	1992-03-05	Fisons Plc	Inhalation device
DE4027391A1 (de)	1990-08-30	1992-03-12	Boehringer Ingelheim Kg	Treibgasfreies inhalationsgeraet
EP0640354B1 (en)	1990-09-26	2001-12-05	Pharmachemie B.V.	Whirl chamber powder inhaler
GB9026025D0 (en)	1990-11-29	1991-01-16	Boehringer Ingelheim Kg	Inhalation device
AU650953B2 (en)	1991-03-21	1994-07-07	Novartis Ag	Inhaler
DE4239402A1 (de)	1992-11-24	1994-05-26	Bayer Ag	Pulverinhalator
MY115140A (en)	1992-12-18	2003-04-30	Schering Corp	Inhaler for powdered medications
EP0837710B1 (en)	1995-06-21	2001-11-28	ASTA Medica Aktiengesellschaft	Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments
DE10129703A1 (de)	2001-06-22	2003-01-02	Sofotec Gmbh & Co Kg	Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
ITMI20010357U1 (it)	2001-06-28	2002-12-30	Plastiape Spa	Dispositivo inalatore
ES2195785B1 (es)	2002-05-16	2005-03-16	Almirall Prodesfarma, S.A.	Nuevos derivados de piridazin-3(2h)-ona.
ES2211344B1 (es)	2002-12-26	2005-10-01	Almirall Prodesfarma, S.A.	Nuevos derivados de piridazin-3(2h)-ona.
MXPA06003376A (es) *	2003-09-26	2006-06-08	Schering Corp	Tratamiento de enfermedad pulmonar.
ES2232306B1 (es)	2003-11-10	2006-08-01	Almirall Prodesfarma, S.A.	Nuevos derivados de piridazin-3(2h)-ona.
GB0410712D0 (en)	2004-05-13	2004-06-16	Novartis Ag	Organic compounds
ES2251866B1 (es)	2004-06-18	2007-06-16	Laboratorios Almirall S.A.	Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es)	2004-06-21	2007-06-16	Laboratorios Almirall S.A.	Nuevos derivados de piridazin-3(2h)-ona.
ATE481996T1 (de)	2004-07-16	2010-10-15	Almirall Sa	Inhalator für die abgabe von pharmzeutischen pulver, und ein pulverkassette zur verwendung mit diesem inhalator
ES2265276B1 (es)	2005-05-20	2008-02-01	Laboratorios Almirall S.A.	Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2306595B1 (es) *	2007-02-09	2009-09-11	Laboratorios Almirall S.A.	Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
EP2100598A1 (en) *	2008-03-13	2009-09-16	Laboratorios Almirall, S.A.	Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2196465A1 (en)	2008-12-15	2010-06-16	Almirall, S.A.	(3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
UY32297A (es)	2008-12-22	2010-05-31	Almirall Sa	Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2221297A1 (en) *	2009-02-18	2010-08-25	Almirall, S.A.	5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases
EP2221055A1 (en) *	2009-02-18	2010-08-25	Almirall, S.A.	5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function

2012
- 2012-05-31 EP EP12382221.5A patent/EP2668941A1/en not_active Withdrawn
2013
- 2013-05-30 CN CN201380028903.4A patent/CN104394852A/zh active Pending
- 2013-05-30 US US14/404,199 patent/US20150140099A1/en not_active Abandoned
- 2013-05-30 EA EA201401354A patent/EA201401354A1/ru unknown
- 2013-05-30 SG SG10201913424SA patent/SG10201913424SA/en unknown
- 2013-05-30 MY MYPI2014703543A patent/MY184654A/en unknown
- 2013-05-30 JP JP2015514503A patent/JP6272836B2/ja not_active Expired - Fee Related
- 2013-05-30 CA CA2871358A patent/CA2871358C/en active Active
- 2013-05-30 NZ NZ701261A patent/NZ701261A/en not_active IP Right Cessation
- 2013-05-30 EP EP13728344.6A patent/EP2854771A1/en not_active Withdrawn
- 2013-05-30 KR KR1020187026487A patent/KR20180104197A/ko not_active Application Discontinuation
- 2013-05-30 BR BR112014029735A patent/BR112014029735A2/pt not_active Application Discontinuation
- 2013-05-30 AU AU2013269565A patent/AU2013269565B2/en not_active Ceased
- 2013-05-30 SG SG11201407110QA patent/SG11201407110QA/en unknown
- 2013-05-30 PE PE2014002064A patent/PE20150171A1/es not_active Application Discontinuation
- 2013-05-30 MX MX2014014350A patent/MX2014014350A/es unknown
- 2013-05-30 KR KR1020147033563A patent/KR20150018526A/ko active Application Filing
- 2013-05-30 WO PCT/EP2013/061181 patent/WO2013178742A1/en active Application Filing
- 2013-05-30 IN IN8672DEN2014 patent/IN2014DN08672A/en unknown
- 2013-05-30 SG SG10201609119VA patent/SG10201609119VA/en unknown
- 2013-05-30 TW TW102119230A patent/TWI610690B/zh not_active IP Right Cessation
- 2013-05-31 AR ARP130101927 patent/AR091233A1/es unknown
- 2013-05-31 UY UY0001034838A patent/UY34838A/es not_active Application Discontinuation
2014
- 2014-10-13 ZA ZA2014/07405A patent/ZA201407405B/en unknown
- 2014-11-20 IL IL235831A patent/IL235831B/en active IP Right Grant
- 2014-11-25 NI NI201400139A patent/NI201400139A/es unknown
- 2014-11-26 EC ECIEPI201428814A patent/ECSP14028814A/es unknown
- 2014-11-26 DO DO2014000271A patent/DOP2014000271A/es unknown
- 2014-11-26 CR CR20140540A patent/CR20140540A/es unknown
- 2014-11-27 CO CO14260864A patent/CO7141434A2/es unknown
- 2014-11-28 CL CL2014003286A patent/CL2014003286A1/es unknown
- 2014-11-28 PH PH12014502662A patent/PH12014502662A1/en unknown
2015
- 2015-04-16 HK HK15103713.3A patent/HK1203149A1/xx unknown
2016
- 2016-06-30 US US15/198,289 patent/US20160303108A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PH12014502662A1 (en)	2015-02-02
CO7141434A2 (es)	2014-12-12
MY184654A (en)	2021-04-14
TWI610690B (zh)	2018-01-11
IL235831A0 (en)	2015-01-29
CL2014003286A1 (es)	2015-02-20
MX2014014350A (es)	2015-03-03
AR091233A1 (es)	2015-01-21
US20150140099A1 (en)	2015-05-21
CA2871358C (en)	2020-09-29
UY34838A (es)	2014-03-31
WO2013178742A1 (en)	2013-12-05
TW201347789A (zh)	2013-12-01
US20160303108A1 (en)	2016-10-20
EA201401354A1 (ru)	2015-05-29
JP2015519356A (ja)	2015-07-09
AU2013269565A1 (en)	2014-10-30
ECSP14028814A (es)	2015-12-31
CN104394852A (zh)	2015-03-04
DOP2014000271A (es)	2015-02-27
NI201400139A (es)	2015-12-10
KR20150018526A (ko)	2015-02-23
KR20180104197A (ko)	2018-09-19
EP2854771A1 (en)	2015-04-08
BR112014029735A2 (pt)	2017-06-27
SG10201609119VA (en)	2016-12-29
PE20150171A1 (es)	2015-01-31
CA2871358A1 (en)	2013-12-05
JP6272836B2 (ja)	2018-01-31
AU2013269565B2 (en)	2017-07-20
IN2014DN08672A (xx)	2015-05-22
CR20140540A (es)	2015-01-16
SG10201913424SA (en)	2020-03-30
SG11201407110QA (en)	2014-12-30
IL235831B (en)	2020-09-30
EP2668941A1 (en)	2013-12-04
ZA201407405B (en)	2015-11-25
NZ701261A (en)	2016-08-26

Publication	Publication Date	Title
HK1255336A1 (zh)	2019-08-16	藥物製劑及其製備方法
IL245780A0 (en)	2016-08-02	Carbamoylpyridone-polycyclic compounds and their pharmaceutical use
HK1213798A1 (zh)	2016-07-15	治療性化合物和組合物
HK1213591A1 (zh)	2016-07-08	生物粘合劑的製備和應用
HK1211206A1 (en)	2016-05-20	Virus-containing formulation and use thereof
IL252566A0 (en)	2017-07-31	Pharmacy preparations and methods
HK1203149A1 (en)	2015-10-23	Novel dosage form and formulation of abediterol
HK1206623A1 (en)	2016-01-15	Pharmaceutical compositions and treatment of mastitis
EP2953605A4 (en)	2016-03-02	USE OF A COSMETIC COMPOSITION
HK1215793A1 (zh)	2016-09-15	的凍乾製劑
HK1203050A1 (en)	2015-10-16	Novel dosage and formulation
HK1206646A1 (en)	2016-01-15	Dosage forms of halofuginone and methods of use
IL233961A0 (en)	2014-09-30	The composition of a phytogenic supplement and methods of its use
GB201208315D0 (en)	2012-06-27	Pharmaceutical methods and compositions
ZA201408128B (en)	2015-12-23	Etract of greyia radlkoferi and use thereof
EP2862571A4 (en)	2016-03-16	CAMPTOTHECIN COMPOUND, AND ITS MANUFACTURE AND USE
EP2814907A4 (en)	2015-11-04	BORBASTLASTED LIQUID SCINTILLATE COMPOSITIONS AND METHOD OF MANUFACTURING THEREOF
EP2884963A4 (en)	2016-04-06	STABLE PHARMACEUTICAL FORMULATION OF CABAZITAXEL
GB201207064D0 (en)	2012-06-06	Pharmaceutical compositions comprising 15-hetre and methods of using the same
EP2841164A4 (en)	2015-12-02	COMPOSITIONS AND USE PROCEDURES FOR THE SKIN